BioNTech Enterprise Value Over E B I T D A from 2010 to 2024

BNTX Stock  USD 86.17  0.23  0.27%   
BioNTech Enterprise Value Over EBITDA yearly trend continues to be fairly stable with very little volatility. Enterprise Value Over EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioNTech Enterprise Value Over EBITDA regression line of annual values had significance of  0.78 and arithmetic mean of (57.88). View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
9.97782443
Current Value
10.48
Quarterly Volatility
85.73699764
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many exotic indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0113 or PTB Ratio of 1.19. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
This module can also supplement BioNTech's financial leverage analysis and stock options assessment as well as various BioNTech Technical models . Check out the analysis of BioNTech Correlation against competitors.

Latest BioNTech's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of BioNTech SE over the last few years. It is BioNTech's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Very volatile
   Enterprise Value Over E B I T D A   
       Timeline  

BioNTech Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(57.88)
Coefficient Of Variation(148.12)
Mean Deviation42.13
Median(52.71)
Standard Deviation85.74
Sample Variance7,351
Range360
R-Value0.08
Mean Square Error7,868
R-Squared0.01
Significance0.78
Slope1.50
Total Sum of Squares102,912

BioNTech Enterprise Value Over E B I T D A History

2024 10.48
2023 9.98
2022 1.57
2021 3.62
2020 -349.81
2019 -40.48
2018 -81.94

About BioNTech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include BioNTech income statement, its balance sheet, and the statement of cash flows. BioNTech investors use historical funamental indicators, such as BioNTech's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although BioNTech investors may use each financial statement separately, they are all related. The changes in BioNTech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioNTech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BioNTech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 9.98  10.48 

Pair Trading with BioNTech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.

Moving together with BioNTech Stock

  0.72JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr
  0.77PFE Pfizer Inc Sell-off TrendPairCorr

Moving against BioNTech Stock

  0.56NUVB Nuvation Bio Financial Report 2nd of May 2024 PairCorr
  0.51JSPRW Jasper TherapeuticsPairCorr
  0.48IOVA Iovance Biotherapeutics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:
Check out the analysis of BioNTech Correlation against competitors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for BioNTech Stock analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.80)
Earnings Share
4.07
Revenue Per Share
15.873
Quarterly Revenue Growth
(0.65)
Return On Assets
0.0262
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.